ArticleBiologics : targets & therapy2024

Feasibility and Tolerability of Anlotinib Plus PD-1 Inhibitors for Previously-Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.

Hai-Li Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.